Skip to main content

Table 1 Baseline characteristics of study subjects

From: Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes

  Normal glucose tolerance Type 2 diabetes Type 2 diabetes P-value
    without carotid plaque with carotid plaque  
  (N = 30) (N = 30) (N = 30)  
Age (years) 54.07 ± 8.14 53.1 ± 6.81 56.47 ± 6.04 0.169
Gender (M:F) 12 : 18 10 : 20 15 : 15 0.418
BMI (kg/m2) 23.99 ± 2.88 23.89 ± 2.29 24.18 ± 2.11 0.895
Waist circumference (cm) 85.19 ± 6.05a 93.68 ± 6.76b 95.12 ± 3.98 b < 0.001
SBP (mmHg) 119.67 ± 12.73 a 119.33 ± 10.56 a 129.83 ± 17.95 b 0.007
DBP (mmHg) 77.67 ± 10.06 74.5 ± 8.55 77.72 ± 9.92 0.332
Fasting blood glucose (mmol/L) 5.16 ± 0.55 a 7.06 ± 2.06 b 7.28 ± 1.53 b < 0.001
HOMA_IR 1.66 (0.92, 2.52) a 2.7 (1.91, 4.10) b 2.96 (1.92, 3.86) b 0.002
HbA1c 5.68 ± 0.34 a 7.27 ± 1.04 b 7.4 ± 0.94 b < 0.001
LDL cholesterol (mmol/L) 2.58 ± 0.81 2.28 ± 0.60 2.27 ± 0.50 0.122
HDL cholesterol (mmol/L) 1.41 ± 0.39 1.24 ± 0.34 1.29 ± 0.27 0.159
Triglyceride (mmol/L) 1.02 (0.70, 1.56) 1.17 (0.98, 2.29) 1.36 (1.02, 1.68) 0.057
hsCRP (mg/dL) 0.56 (0.34, 1.45) 0.57 (0.35, 1.21) 0.45 (0.30, 1.13) 0.428
Carotid IMT (cm) 0.84 ± 0.11 a 0.86 ± 0.12 a 0.98 ± 0.16 b < 0.001
baPWV (m/sec) 13.26 ± 1.77 a 14.29 ± 2.57 a 16.22 ± 3.07 b < 0.001
Current smoker (%) 26.77 30 46.67 0.218
Statin (%) 10.00 a 33.33 ab 40.44 b 0.024
Anti-platelet agent (%) 6.67 6.67 26.67 0.031
ARB or ACE inhibitor (%) 10.00 a 16.67 ab 40.00 b 0.013
Calcium channel blocker (%) 10 13.33 20 0.533
Insulin (%) - 13.33 16.66 0.718
Sulfonylurea (%) - 33.33 43.33 0.426
Glucophage (%) - 53.33 56.66 0.795
Thiazolidinedione (%) - 10 13.33 0.688
Duration of diabetes (years) - 8.47 ± 5.46 12.17 ± 7.35 < 0.001
  1. Data are expressed as the mean with SD, median (inter-quartile range), or percentage. P-value for overall difference among the groups was calculated from the analysis of variance (ANOVA), the Kruskal-Wallis H test, or Pearson's chi-square test. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoproteins; hsCRP, high sensitivity C-reactive protein; IMT, intima-media thickness; baPWV, brachial ankle pulse wave velocity; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme inhibitor.
  2. a, b, c: same letter indicates no statistical difference between the groups based on post hoc analysis.